NASDAQ:ORIC Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis $7.36 -0.34 (-4.42%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$7.36 0.00 (0.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oric Pharmaceuticals Stock (NASDAQ:ORIC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oric Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.28▼$8.0050-Day Range$7.36▼$13.8552-Week Range$7.23▼$14.68Volume1.46 million shsAverage Volume1.97 million shsMarket Capitalization$762.89 millionP/E RatioN/ADividend YieldN/APrice Target$20.18Consensus RatingModerate Buy Company Overview Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines. Founded in 2014, Oric is headquartered in South San Francisco, California. It conducts research and clinical development of its drug candidates, with clinical studies involving patients in multiple regions.AI Generated. May Contain Errors. Read More Oric Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreORIC MarketRank™: 2.71758934828 of 5 starsOric Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 422nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOric Pharmaceuticals has a consensus price target of $20.18, representing about 174.2% upside from its current price of $7.36.Amount of Analyst CoverageOric Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oric Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.60) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oric Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oric Pharmaceuticals is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOric Pharmaceuticals has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.98% of the float of Oric Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOric Pharmaceuticals has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Oric Pharmaceuticals has recently decreased by 30.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOric Pharmaceuticals does not currently pay a dividend.Dividend GrowthOric Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.20 News SentimentOric Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oric Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,432,952.00 in company stock.Percentage Held by Insiders5.70% of the stock of Oric Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oric Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORIC Stock News HeadlinesHC Wainwright Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock PriceNovember 21 at 2:44 AM | americanbankingnews.comWells Fargo & Company Issues Pessimistic Forecast for Oric Pharmaceuticals (NASDAQ:ORIC) Stock PriceNovember 20 at 2:44 AM | americanbankingnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 22 at 1:00 AM | Decentralized Masters (Ad)ORIC Pharmaceuticals (ORIC) Stock Price Target 2026November 19 at 3:36 PM | benzinga.comBTIG Research Reaffirms "Buy" Rating for Oric Pharmaceuticals (NASDAQ:ORIC)November 19 at 3:56 AM | americanbankingnews.comCitigroup Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) StockNovember 19 at 2:24 AM | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 4.1% Following Analyst UpgradeNovember 19 at 1:40 AM | americanbankingnews.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Consensus Price Target of $21.33November 18, 2026 | americanbankingnews.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? Oric Pharmaceuticals' stock was trading at $8.18 at the start of the year. Since then, ORIC stock has decreased by 10.0% and is now trading at $7.36. How were Oric Pharmaceuticals' earnings last quarter? Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.05. When did Oric Pharmaceuticals IPO? Oric Pharmaceuticals (ORIC) raised $112 million in an IPO on Friday, April 24th 2020. The company issued 7,500,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. Who are Oric Pharmaceuticals' major shareholders? Oric Pharmaceuticals' top institutional shareholders include State Street Corp (3.98%), Goldman Sachs Group Inc. (1.74%), Integral Health Asset Management LLC (1.64%) and Algert Global LLC (1.56%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You. View institutional ownership trends. How do I buy shares of Oric Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oric Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoFi Technologies (SOFI), Viking Therapeutics (VKTX), Micron Technology (MU), Advanced Micro Devices (AMD) and Compass Pathways (CMPS). Company Calendar Last Earnings11/16/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ORIC's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORIC CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees111Year Founded2014Price Target and Rating Average Price Target for Oric Pharmaceuticals$20.18 High Price Target$26.00 Low Price Target$14.00 Potential Upside/Downside+174.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.99% Return on Assets-38.54% Debt Debt-to-Equity RatioN/A Current Ratio11.09 Quick Ratio13.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book2.24Miscellaneous Outstanding Shares103,653,000Free Float97,745,000Market Cap$762.89 million OptionableOptionable Beta1.23 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ORIC) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.